2 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow ABX464: new trials by email Literature Review of ABX464 trials Research Report on ABX464
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 636 | 2023-01-25 | 2026-09-10 |
| ABTECT - Maintenance ABX464, Placebo - Ulcerative Colitis | Phase 3 | Active not recruiting | Abivax S.A. | 1116 | 2023-01-16 | 2026-07-07 |
| ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 639 | 2022-11-16 | 2026-09-10 |
| Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients ABX464, Placebo - Crohn Disease | Phase 2 / Phase 3 | Withdrawn | Abivax S.A. | 2022-09-19 | 2024-07-31 | |
| ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 ABX464, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Abivax S.A. | 509 | 2020-07-01 | 2025-11-26 |
Colitis, Ulcerative (3) · COVID-19 (1) · Crohn Disease (1)
Abivax S.A. (5)
Belgium (5) · France (4) · Germany (4) · Italy (4) · Spain (4) · United Kingdom (4) · Argentina (3) · Brazil (3) · Bulgaria (3) · Canada (3) · Czechia (3) · Hungary (3) · India (3) · Mexico (3) · Poland (3)